African scientists' search for female-controlled microbicide gel to prevent HIV continues

NewsGuard 100/100 Score

AllAfrica.com examines efforts by African researchers to develop a female-controlled HIV prevention method, writing, "[S]cientists searching for a gel or vaccine that can prevent HIV infection ride a rollercoaster of hope and disappointment." The article profiles efforts by researchers from the Centre for the AIDS Program of Research in South Africa (Caprisa) to find a microbicide gel to protect women from HIV infection.

In a study announced at the 2010 International AIDS Conference, a tenofovir vaginal gel "was able to reduce sexual transmission of the virus by 39 percent overall and 54 percent in women who used it consistently," the news service notes. "But the euphoria over this breakthrough has dissolved into disappointment," with the November 2011 suspension of another study, the Vaginal and Oral Interventions to Control the Epidemic (Voice) trial, in which the gel was used daily but was shown not to reduce the risk of HIV infection, the news service writes. According to allAfrica.com, "another trial is underway: the Facts study (Follow-on African Consortium for Tenofovir Studies), funded by the South African government, USAID and the Bill & Melinda Gates Foundation" (Frederickse et al., 2/2).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New report on HIV drug resistance: Challenges and recommendations